Xencor Inc
For the period ended Dec 31, 2025. Filed Feb 25, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 25, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Power of Attorney (included on signature page herein)
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints, jointly and severally, Bassil I. Dahiyat, Ph.D. and Bart Jan Cornelissen, and each of them acting individually, as his or her true and lawful attorneys-in-fact, each with full power of substitution and resubstitution, for him or her, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K and to file the same, with all exhibits thereto and all other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact full power and authority to do and perform each and every act and thing requisite or necessary to be done in connection therewith as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that each of said attorneys-in-fact or his or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the Company and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ BASSIL I. DAHIYAT, PH.D. | Director, President & Chief Executive Officer (Principal Executive Officer) | February 25, 2026 |
| Bassil I. Dahiyat, Ph.D. | ||
| /s/ BART JAN CORNELISSEN | Sr. Vice President & Chief Financial Officer (Principal Financial and Accounting Officer) | February 25, 2026 |
| Bart Jan Cornelissen | ||
| /s/ A. BRUCE MONTGOMERY, M.D. | Director | February 25, 2026 |
| A. Bruce Montgomery, M.D. | ||
| /s/ KURT GUSTAFSON | Director | February 25, 2026 |
| Kurt Gustafson | ||
| /s/ KEVIN C. GORMAN, PH.D. | Director | February 25, 2026 |
| Kevin C. Gorman, Ph.D. | ||
| /s/ RICHARD RANIERI | Director | February 25, 2026 |
| Richard Ranieri | ||
| /s/ ELLEN G. FEIGAL, M.D. | Director | February 25, 2026 |
| Ellen G. Feigal, M.D. | ||
| /s/ BARBARA KLENCKE | Director | February 25, 2026 |
| Barbara Klencke | ||
| /s/ TODD SIMPSON | Director | February 25, 2026 |
| Todd Simpson | ||
| /s/ RAYMOND J. DESHAIES | Director | February 25, 2026 |
| Raymond J. Deshaies | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.